Table 1.
Summary of Unbound Evolocumab Pharmacokinetic Parameters After 140 mg SC Evolocumab Every 2 Weeks in Hypercholesterolemic Patients Treated With Low‐ to Moderate‐Intensity or High‐Intensity Statins
| Parameter (Mean ± SD) | Low‐Moderate (n = 6) | High (n = 9) | Ratio (High/Low‐Moderate) |
|---|---|---|---|
| Baseline PCSK9 (ng/mL) | 385 ± 88 | 487 ± 214 | 1.26 |
| Cmax (μg/mL) | 20 ± 13 | 16 ± 11 | 0.80 |
| AUClast (day·μg/mL) | 226 ± 249 | 181 ± 157 | 0.80 |
Low‐moderate: atorvastatin <40 mg, rosuvastatin <20 mg, simvastatin <40 mg, or simvastatin 80 mg. High: atorvastatin 80 mg or rosuvastatin 40 mg. AUClast , area under the concentration‐time curve from time zero to the last quantifiable concentration; Cmax, maximum observed concentration; PCSK9, proprotein convertase subtilisin/kexin type 9.